Table 2.
Baseline patient characteristics by chemotherapy or endocrine therapy groups.
| Characteristics | Chemotherapy group (n = 147) n (%) | Endocrine therapy group (n = 53) n (%) | p-values |
|---|---|---|---|
| Age (years), median, range | 54 (28–82) | 53 (31–78) | 0.503 |
| Menopausal status | |||
| Premenopausal | 48 (32.6) | 15 (28.3) | 0.559 |
| Postmenopausal | 99 (67.4) | 38 (71.7) | |
| Disease-free interval | |||
| Primary metastatic | 16 (10.9) | 9 (17.0) | 0.403 |
| ⩽2 years | 24 (16.3) | 6 (11.3) | |
| >2 years | 107 (72.8) | 38 (71.7) | |
| Metastatic sites | |||
| Lung | 51 (34.7) | 22 (41.5) | 0.377 |
| Liver | 95 (64.6) | 23 (43.3) | 0.007 |
| Number of metastatic sites | |||
| 1 | 26 (17.7) | 13 (24.5) | 0.060 |
| 2 | 35 (23.8) | 19 (35.9) | |
| ⩾3 | 86 (58.5) | 21 (39.6) | |
| Visceral metastases | |||
| Yes | 124 (84.3) | 40 (71.7) | 0.149 |
| No | 23 (15.7) | 13 (28.3) | |
| Lines of advanced systematic therapy of palbociclib | |||
| 1 | 22 (15.0) | 13 (24.5) | 0.089 |
| 2 | 45 (30.6) | 9 (17.0) | |
| ⩾3 | 80 (54.4) | 31 (58.5) | |
| Sensitivity to the previous palbociclib | |||
| Yes | 58 (39.5) | 38 (71.7) | <0.001 |
| No | 89 (60.5) | 15 (28.3) | |